Loading quotes...
Forecast
The analysts' average price target is €22.29 (+295.91%). The median is €22.29 (+295.91%).
| Buy |
10 |
| Hold |
2 |
| Sell |
0 |
News Go to news feed
There is currently no news available for this company. We are working on adding more providers to change this.
Financials
| (EUR) | June 2026 | YoY |
|---|---|---|
| Revenue | 30.25M | 38.76% |
| Gross profit | 30.25M | 40.08% |
| Net profit | -481.92K | 97.97% |
| EBITDA | 13.31M | 215.75% |
Fundamentals
| Metric | Value |
|---|---|
Market capitalization | €262.11M |
Number of shares | 45.16M |
52-week high/low | €9.19 - €2.42 |
| Dividends | No |
Beta | 1.55 |
P/E ratio | 2.40 |
PEG ratio | 0.00 |
P/B ratio | -1.35 |
P/S ratio | 2.22 |
Company profile
| Name | Agenus Inc. |
| CEO | Garo H. Armen |
| Headquarters | Lexington,
ma USA |
| Website | |
| Sector | Health Care |
| Industry | Biotechnology |
| Employees | 81 |
